{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T17:08:39Z","timestamp":1790096919546,"version":"4.0.1"},"reference-count":43,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.drudis.2026.104790","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T07:01:35Z","timestamp":1787814095000},"page":"104790","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Integrating population heterogeneity in drug research and early development: a proactive strategy"],"prefix":"10.1016","volume":"31","author":[{"given":"Thierry","family":"Lav\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Jolain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e9a-Isabelle","family":"Proulx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Santini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana","family":"Bessa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Crowell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Sanwald-Ducray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruma","family":"Bhagat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Richie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2026.104790_b0005","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2024-082486","article-title":"Inclusive research: a path to equity and better outcomes","volume":"388","author":"Anand","year":"2025","journal-title":"BMJ"},{"key":"10.1016\/j.drudis.2026.104790_b0010","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1093\/neuonc\/noac011","article-title":"A population study of clinical trial accrual for women and minorities in neuro-oncology following the NIH Revitalization Act","volume":"24","author":"Reihl","year":"2022","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.drudis.2026.104790_b0015","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/nrd.2017.244","article-title":"Impact of a five-dimensional framework on R&D productivity at AstraZeneca","volume":"17","author":"Morgan","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2026.104790_b0020","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1056\/NEJMsa073350","article-title":"We can do better \u2013 improving the health of the American people","volume":"357","author":"Schroeder","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2026.104790_b0025","doi-asserted-by":"crossref","DOI":"10.1177\/2167702613478594","article-title":"The emerging field of human social genomics","author":"Slavich","year":"2013","journal-title":"Clin Psychol Sci"},{"key":"10.1016\/j.drudis.2026.104790_b0030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001918","article-title":"Diversity in clinical and biomedical research: a promise yet to be fulfilled","volume":"12","author":"Oh","year":"2015","journal-title":"PLoS Med"},{"key":"10.1016\/j.drudis.2026.104790_b0035","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2023.1236462","article-title":"Real-world evidence for regulatory decision-making: updated guidance from around the world","volume":"10","author":"Burns","year":"2023","journal-title":"Front Med"},{"key":"10.1016\/j.drudis.2026.104790_b0040","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1002\/cpt.3350","article-title":"Role of clinical pharmacology in diversity and inclusion in global drug development: current practices and industry perspectives: white paper","volume":"116","author":"Sawant-Basak","year":"2024","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.drudis.2026.104790_b0045","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1002\/cpt.2416","article-title":"Diversity and inclusion in drug development: rethinking intrinsic and extrinsic factors with patient centricity","volume":"112","author":"Venkatakrishnan","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.drudis.2026.104790_b0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2022.106807","article-title":"Ensuring diversity in clinical trials: the role of clinical pharmacology","volume":"118","author":"Masters","year":"2022","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.drudis.2026.104790_b0055","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1111\/bcp.15242","article-title":"Clinical trial diversity: an opportunity for improved insight into the determinants of variability in drug response","volume":"88","author":"Gross","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.drudis.2026.104790_b0060","doi-asserted-by":"crossref","first-page":"3861","DOI":"10.1038\/s41467-021-23998-w","article-title":"In-silico trial of intracranial flow diverters replicates and expands insights from conventional clinical trials","volume":"12","author":"Sarrami-Foroushani","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2026.104790_b0065","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/s41586-021-03430-5","article-title":"Evaluating eligibility criteria of oncology trials using real-world data and AI","volume":"592","author":"Liu","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2026.104790_b0070","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1312889","article-title":"Phase 3 trials of solanezumab for mild-to-moderate Alzheimer\u2019s disease","volume":"370","author":"Doody","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2026.104790_b0075","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa1304839","article-title":"Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer\u2019s disease","volume":"370","author":"Salloway","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2026.104790_b0080","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.1200\/JCO.23.02036","article-title":"Randomized phase III study of amcenestrant plus palbociclib versus letrozole plus palbociclib in estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: primary results from AMEERA-5","volume":"42","author":"Cort\u00e9s","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.drudis.2026.104790_b0085","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1200\/JCO.22.00338","article-title":"Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: results from the randomized phase III EMERALD trial","volume":"40","author":"Bidard","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.drudis.2026.104790_b0090","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/j.0887-378X.2004.00327.x","article-title":"Evidence-based medicine, heterogeneity of treatment effects, and the trouble with averages","volume":"82","author":"Kravitz","year":"2004","journal-title":"Milbank Q"},{"key":"10.1016\/j.drudis.2026.104790_b0095","unstructured":"Chen A. New analysis shows real-world evidence could streamline and accelerate at least one in four postmarketing studies. Published 1 Apr 2024. https:\/\/resources.flatiron.com\/real-world-evidence\/accelerate-postmarketing-studies. Accessed 2 Feb 2026."},{"key":"10.1016\/j.drudis.2026.104790_b0100","doi-asserted-by":"crossref","DOI":"10.1111\/cts.13880","article-title":"How debunking biases in research and development decisions could lead to more equitable healthcare?","volume":"17","author":"Weber","year":"2024","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.drudis.2026.104790_b0105","doi-asserted-by":"crossref","DOI":"10.1111\/cts.70332","article-title":"How clinical pharmacology can support clinical trial diversity and inclusion","volume":"18","author":"Liao","year":"2025","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.drudis.2026.104790_b0110","doi-asserted-by":"crossref","DOI":"10.1002\/psp4.70105","article-title":"Using virtual patients to evaluate dosing strategies for bispecifics with a bell-shaped efficacy curve","author":"Gevertz","year":"2025","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.drudis.2026.104790_b0115","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.annonc.2023.08.008","article-title":"Treatment of evolving cancers will require dynamic decision support","volume":"34","author":"Strobl","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.drudis.2026.104790_b0120","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.ophtha.2023.12.026","article-title":"Faricimab treat-and-extend for diabetic macular edema two-year results from the randomized phase 3 YOSEMITE and RHINE trials","volume":"131","author":"Wong","year":"2024","journal-title":"Ophthalmology"},{"key":"10.1016\/j.drudis.2026.104790_b0125","unstructured":"FDA. Diversity action plans to improve enrollment of participants from underrepresented populations in clinical studies \u2013 draft guidance for industry. Published 1 Jun 2024. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/diversity-action-plans-improve-enrollment-participants-underrepresented-populations-clinical-studies. Accessed 13 March 2026."},{"key":"10.1016\/j.drudis.2026.104790_b0130","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1126\/science.aao2774","article-title":"Patient-derived organoids model treatment response of metastatic gastrointestinal cancers","volume":"359","author":"Vlachogiannis","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.drudis.2026.104790_b0135","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/2159-8290.CD-21-0410","article-title":"Implementing a functional precision medicine tumor board for acute myeloid leukemia","volume":"12","author":"Malani","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.drudis.2026.104790_b0140","doi-asserted-by":"crossref","DOI":"10.1111\/cts.70276","article-title":"Critical roles for modeling and simulation and real-world evidence to inform challenges in clinical trial diversity planning","volume":"18","author":"Kadambi","year":"2025","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.drudis.2026.104790_b0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.conctc.2025.101432","article-title":"Demographic clinical trial diversity assessment methods: use of real-world data","volume":"44","author":"Chen","year":"2025","journal-title":"Contemp Clin Trials Commun"},{"key":"10.1016\/j.drudis.2026.104790_b0150","unstructured":"Denari\u00e9 M, Gemmen E, Bratton E, Goins M, Fones R, Stolper R. Leveraging real-world data to estimate race and ethnicity representation in clinical trial design; 2023. https:\/\/www.iqvia.com\/library\/white-papers\/leveraging-real-world-data-to-estimate-race-and-ethnicity-representation-in-clinical-trial-design. Accessed 20 Dec 2025."},{"key":"10.1016\/j.drudis.2026.104790_b0155","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/psp4.12232","article-title":"Improving realism in clinical trial simulations via real-world data","volume":"6","author":"Kimko","year":"2017","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.drudis.2026.104790_b0160","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1007\/s43441-025-00822-x","article-title":"Hope is not a strategy: using robust real-world evidence to make better clinical development decisions","volume":"59","author":"Gatto","year":"2025","journal-title":"Ther Innov Regul Sci"},{"key":"10.1016\/j.drudis.2026.104790_b0165","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/cpt.70116","article-title":"Enhancing severe neutropenia prediction: PKPD-informed labeling for machine learning models trained on real-world data","volume":"119","author":"O\u2019Hanlon","year":"2026","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.drudis.2026.104790_b0170","doi-asserted-by":"crossref","first-page":"12236","DOI":"10.1038\/s41598-024-62567-1","article-title":"ClinicalGAN: powering patient monitoring in clinical trials with patient digital twins","volume":"14","author":"Chandra","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.drudis.2026.104790_b0175","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/s41540-025-00592-0","article-title":"Enhancing randomized clinical trials with digital twins","volume":"11","author":"Akbarialiabad","year":"2025","journal-title":"npj Syst Biol Appl"},{"key":"10.1016\/j.drudis.2026.104790_b0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbi.2025.104879","article-title":"Digital twins in increasing diversity in clinical trials: a systematic review","volume":"169","author":"Tubbs","year":"2025","journal-title":"J Biomed Inform"},{"key":"10.1016\/j.drudis.2026.104790_b0185","doi-asserted-by":"crossref","DOI":"10.2196\/50204","article-title":"Envisioning the future of personalized medicine: role and realities of digital twins","volume":"26","author":"Vall\u00e9e","year":"2024","journal-title":"J Med Internet Res"},{"key":"10.1016\/j.drudis.2026.104790_b0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2025.104322","article-title":"Embracing the future of medicine with virtual patients","volume":"30","author":"Wang","year":"2025","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.drudis.2026.104790_b0195","unstructured":"Graaf P van der. Virtual triplets: the next step in personalized and ethical drug development. Published 9 Dec 2025. https:\/\/www.certara.com\/blog\/virtual-triplets-the-next-step-in-personalized-and-ethical-drug-development\/. Accessed 20 December 2025."},{"key":"10.1016\/j.drudis.2026.104790_b0200","doi-asserted-by":"crossref","first-page":"4727","DOI":"10.1007\/s12325-025-03283-8","article-title":"Five data-informed principles for advancing inclusive research in clinical trials: a pharma perspective","volume":"42","author":"James","year":"2025","journal-title":"Adv Ther"},{"key":"10.1016\/j.drudis.2026.104790_b0205","doi-asserted-by":"crossref","first-page":"613","DOI":"10.2165\/11592640-000000000-00000","article-title":"Development of a physiologically based model for oseltamivir and simulation of pharmacokinetics in neonates and infants","volume":"50","author":"Parrott","year":"2011","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.drudis.2026.104790_b0210","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1002\/psp4.12669","article-title":"Scientific and regulatory evaluation of mechanistic in silico drug and disease models in drug development: building model credibility","volume":"10","author":"Musuamba","year":"2021","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.drudis.2026.104790_b0215","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1002\/cpt.3636","article-title":"Impact of model-informed drug development on drug development cycle times and clinical trial cost","volume":"118","author":"Sahasrabudhe","year":"2025","journal-title":"Clin Pharmacol Ther"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644626001959?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644626001959?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T16:17:57Z","timestamp":1790093877000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644626001959"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":43,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1359644626001959"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2026.104790","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Integrating population heterogeneity in drug research and early development: a proactive strategy","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2026.104790","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104790"}}